Nicholas Investment Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Nicholas Investment Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-117,087	Closed	-$3.73M	–	269
2016 Q3	$3.73M	Sell	117,087 -9,000	-7%	-$305K	0.25%	162
2016 Q2	$4.09M	Buy	+126,087	New	+$4.22M	0.28%	132
2016 Q1	–	Sell	-55,254	Closed	-$1.97M	–	299
2015 Q4	$1.97M	Buy	+55,254	New	+$1.95M	0.14%	257
2015 Q3	–	Sell	-43,964	Closed	-$1.84M	–	295
2015 Q2	$1.84M	Sell	43,964 -14,059	-24%	-$544K	0.12%	272
2015 Q1	$1.89M	Buy	+58,023	New	+$1.99M	0.12%	261

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Nicholas Investment Partners's ACAD Position: Q4 2016 in Review

Nicholas Investment Partners sold out of Acadia Pharmaceuticals (ACAD) in Q4 2016, closing a stake of 117,087 shares — an estimated $3.73M sold.

Nicholas Investment Partners first reported a position in ACAD in Q1 2015 and held it in 5 quarters. The position peaked at $4.09M in Q2 2016. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

Nicholas Investment Partners reported no remaining Acadia Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Nicholas Investment Partners sold 117,087 Acadia Pharmaceuticals shares in Q4 2016, an estimated $3.73M.
Nicholas Investment Partners first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 5 quarters.
Nicholas Investment Partners's Acadia Pharmaceuticals position peaked at $4.09M in Q2 2016.
225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on Nicholas Investment Partners's 13F filing for Q4 2016, filed 10 Feb 2017.